SEC ownership of LeonaBio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001620463.
- CIK
- 0001620463
- Symbol
- LONA on Nasdaq
- Location
- Bothell, WA
- Parsed ownership evidence
- 13F, 13D/G, and 3/4/5
- Lead holder
- PERCEPTIVE ADVISORS LLC
- 13D/G signal
- PERCEPTIVE ADVISORS LLC
- Latest evidence date
- 09 Apr 2026
Ownership snapshot
Top shareholders of LeonaBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with the largest verified stakes, then open the linked filing trail.
Lead holder
PERCEPTIVE ADVISORS LLC
13D/G signal
PERCEPTIVE ADVISORS LLC
Evidence rows
50
Latest as of
09 Apr 2026
13F
13D/G
3/4/5
Lead comparable stake: 20%
13D/G row: PERCEPTIVE ADVISORS LLC
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
20%
from 13D/G
|
$19,113,830
1,859,322 shares
|
— | 31 Mar 2026 |
| ADAR1 Capital Management, LLC |
13F
13D/G
Company
|
7.7%
from 13D/G
|
$7,478,505
727,481 shares
|
— | 31 Mar 2026 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
6.2%
|
$1,345,504
596,068 shares
|
+$212,929 | 06 Jan 2026 |
| Steven Michael Oliveira |
13D/G
Oliveira Steven Michael
|
4.1%
|
$69,324
161,218 shares
|
-$788,375 | 01 Oct 2025 |
| Baselake Partners, LP |
13D/G
|
1.9%
|
$573,723
75,789 shares
|
-$921,208 | 31 Dec 2025 |
| ACORN CAPITAL ADVISORS, LLC |
13F
Company
|
6.7%
|
$6,523,061
634,539 shares
|
— | 31 Mar 2026 |
| Commodore Capital LP |
13F
Company
|
4.9%
|
$4,774,011
464,398 shares
|
— | 31 Mar 2026 |
| NEA Management Company, LLC |
13F
Company
|
4.9%
|
$4,774,011
464,398 shares
|
— | 31 Mar 2026 |
| TCG Crossover Management, LLC |
13F
Company
|
4.9%
|
$4,666,596
464,398 shares
|
— | 31 Mar 2026 |
| Kalehua Capital Management LLC |
13F
Company
|
4.2%
|
$4,047,246
393,701 shares
|
— | 31 Mar 2026 |
| Spruce Street Capital LP |
13F
Company
|
4.2%
|
$3,844,884
393,701 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.1%
|
$2,002,133
194,760 shares
|
— | 31 Mar 2026 |
| Seven Fleet Capital Management LP |
13F
Company
|
1.7%
|
$1,692,869
164,676 shares
|
— | 31 Mar 2026 |
| Simplify Asset Management Inc. |
13F
Company
|
1.6%
|
$1,534,588
149,279 shares
|
— | 31 Mar 2026 |
| Propel Bio Management, LLC |
13F
Company
|
1.6%
|
$1,495,776
149,279 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.85%
|
$826,214
80,323 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.68%
|
$660,202
64,222 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
0.59%
|
$576,204
56,051 shares
|
— | 31 Mar 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.42%
|
$411,601
40,039 shares
|
— | 31 Mar 2026 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
0.34%
|
$334,778
32,566 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.34%
|
$325,650
31,678 shares
|
— | 31 Mar 2026 |
| Laird Norton Wetherby Trust Company, LLC |
13F
Company
|
0.23%
|
$224,289
21,818 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
0.17%
|
$167,944
16,337 shares
|
— | 31 Mar 2026 |
| NORTHERN TRUST CORP |
13F
Company
|
0.15%
|
$147,970
14,394 shares
|
— | 31 Mar 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
0.14%
|
$136,477
13,276 shares
|
— | 31 Mar 2026 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
0.11%
|
$105,000
10,230 shares
|
— | 31 Mar 2026 |
| OSAIC HOLDINGS, INC. |
13F
Company
|
0.07%
|
$63,530
6,180 shares
|
— | 31 Mar 2026 |
| ROYAL BANK OF CANADA |
13F
Company
|
0.02%
|
$23,000
2,225 shares
|
— | 31 Mar 2026 |
| Vanguard Global Advisers, LLC |
13F
Company
|
0.01%
|
$13,621
1,325 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.01%
|
$13,353
1,299 shares
|
— | 31 Mar 2026 |
| Annis Gardner Whiting Capital Advisors, LLC |
13F
Company
|
0.01%
|
$10,280
1,000 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$4,842
471 shares
|
— | 31 Mar 2026 |
| American Capital Advisory, LLC |
13F
Company
|
0%
|
$2,056
200 shares
|
— | 31 Mar 2026 |
| ROTHSCHILD INVESTMENT LLC |
13F
Company
|
0%
|
$1,542
150 shares
|
— | 31 Mar 2026 |
| McIlrath & Eck, LLC |
13F
Company
|
0%
|
$843
82 shares
|
— | 31 Mar 2026 |
| US BANCORP \DE\ |
13F
Company
|
0%
|
$833
81 shares
|
— | 31 Mar 2026 |
| JONES FINANCIAL COMPANIES LLLP |
13F
Company
|
0%
|
$296
33 shares
|
— | 31 Mar 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
0%
|
$236
23 shares
|
— | 31 Mar 2026 |
| SBI Securities Co., Ltd. |
13F
Company
|
0%
|
$123
12 shares
|
— | 31 Mar 2026 |
| JPMORGAN CHASE & CO |
13F
Company
|
0%
|
$111
12 shares
|
— | 31 Mar 2026 |
| Caitong International Asset Management Co., Ltd |
13F
Company
|
0%
|
$62
6 shares
|
— | 31 Mar 2026 |
| CITIGROUP INC |
13F
Company
|
0%
|
$10
1 shares
|
— | 31 Mar 2026 |
| Mark James Litton |
3/4/5
PRESIDENT and CEO, Director
|
—
mixed-class rows
|
$445,121
809,894 shares
mixed-class rows
|
-$52,853 | 09 Apr 2026 |
| Hans Moebius |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$266,213
91,482 shares
|
— | 04 Jan 2024 |
| Kelly A. Romano |
3/4/5
Director
|
—
mixed-class rows
|
$194,951
108,715 shares
mixed-class rows
|
— | 09 Apr 2026 |
| Kevin Church |
3/4/5
CHIEF SCIENTIFIC OFFICER
|
—
mixed-class rows
|
$168,112
325,178 shares
mixed-class rows
|
-$15,827 | 09 Apr 2026 |
| Mark Worthington |
3/4/5
GENERAL COUNSEL and CCO
|
—
mixed-class rows
|
$130,855
318,376 shares
mixed-class rows
|
-$15,661 | 09 Apr 2026 |
| Javier San Martin |
3/4/5
CHIEF MEDICAL OFFICER
|
—
mixed-class rows
|
$126,995
365,887 shares
mixed-class rows
|
-$23,729 | 09 Apr 2026 |
| Robert Renninger |
3/4/5
CHIEF FINANCIAL OFFICER
|
—
mixed-class rows
|
$107,033
315,851 shares
mixed-class rows
|
-$7,759 | 09 Apr 2026 |
| Andrew Gengos |
3/4/5
CFO and Chief Business Officer
|
—
mixed-class rows
|
$55,203
377,532 shares
mixed-class rows
|
— | 03 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$115,829.
Buys
$0
Insiders: 0
Sells
$115,829
Insiders: 5
Net
-$115,829
Shares: -72,662
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 72,662
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 10,469 | $0 | $56,219 | -$56,219 |
| 3-6 | 0 | 6,279 | $0 | $43,200 | -$43,200 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 55,914 | $0 | $16,411 | -$16,411 |
LeonaBio, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director, 10%+ Owner | $17,718,931 | Mixed | 23 Dec 2025 | ||
| Mark James Litton | PRESIDENT and CEO, Director | $445,121 | -$52,853 | -11% | Mixed | 09 Apr 2026 |
| Hans Moebius | Chief Medical Officer | $266,213 | Mixed | 04 Jan 2024 | ||
| Kelly A. Romano | Director | $194,951 | Filing P/S | 09 Apr 2026 | ||
| Kevin Church | Chief Scientific Officer | $168,112 | -$15,827 | -8.6% | Mixed | 09 Apr 2026 |
| Mark Worthington | GENERAL COUNSEL and CCO | $130,855 | -$15,661 | -11% | Mixed | 09 Apr 2026 |
| Javier San Martin | Chief Medical Officer | $126,995 | -$23,729 | -16% | Mixed | 09 Apr 2026 |
| Robert Renninger | Chief Financial Officer | $107,033 | -$7,759 | -6.8% | Mixed | 09 Apr 2026 |
| Andrew Gengos | CFO and Chief Business Officer | $55,203 | Filing P/S | 03 Sep 2024 | ||
| Rachel Lenington | COO and CDO | $11,812 | Filing P/S | 03 Sep 2024 | ||
| Glenna Mileson | Chief Financial Officer | Mixed | 19 Jan 2023 | |||
| Tadataka Yamada | Director | Mixed | 28 May 2021 | |||
| Barbara Kosacz | Director | Mixed | 09 Apr 2026 | |||
| John M. Fluke Jr. | Director | Mixed | 09 Apr 2026 | |||
| James A. Johnson | Director | Mixed | 09 Apr 2026 | |||
| Peter B. Silverman | Director | Mixed | 05 May 2026 | |||
| Joseph Edelman | Director | Mixed | 09 Apr 2026 | |||
| Grant Pickering | Director | Mixed | 09 Apr 2026 | |||
| Fred P. Callori | Director | Mixed | 05 May 2026 | |||
| Natalie C. Holles | Director | Mixed | 05 May 2026 | |||
| Michael A. Panzara | Director | Mixed | 09 Apr 2026 |
Recent Insider Transactions by Companies or Individuals for LeonaBio, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Natalie C. Holles | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Peter B. Silverman | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Fred P. Callori | LONA | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 05 May 2026 | Direct | |||
| Michael A. Panzara | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Kevin Church | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Barbara Kosacz | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Grant Pickering | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Kelly A. Romano | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| James A. Johnson | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Joseph Edelman | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Javier San Martin | LONA | Stock Option (Right to Buy) | Award | 350,000 | 350,000 | 09 Apr 2026 | Direct | |||
| John M. Fluke Jr. | LONA | Stock Option (Right to Buy) | Award | 28,000 | 28,000 | 09 Apr 2026 | Direct | |||
| Mark Worthington | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Robert Renninger | LONA | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 09 Apr 2026 | Direct | |||
| Mark James Litton | LONA | Stock Option (Right to Buy) | Award | 750,000 | 750,000 | 09 Apr 2026 | Direct | |||
| Mark James Litton | LONA | Common Stock | Sale | -8.17% | $27,688 | $5.37 | -5,156 | 57,926 | 04 Mar 2026 | Direct |
| Robert Renninger | LONA | Common Stock | Sale | -5.41% | $4,865 | $5.37 | -906 | 15,851 | 04 Mar 2026 | Direct |
| Mark Worthington | LONA | Common Stock | Sale | -6.74% | $7,131 | $5.37 | -1,328 | 18,376 | 04 Mar 2026 | Direct |
| Kevin Church | LONA | Common Stock | Sale | -5.12% | $7,298 | $5.37 | -1,359 | 25,178 | 04 Mar 2026 | Direct |
| Javier San Martin | LONA | Common Stock | Sale | -9.77% | $9,236 | $5.37 | -1,720 | 15,887 | 04 Mar 2026 | Direct |
| Mark James Litton | LONA | Common Stock | Options Exercise | 54.5% | 22,254 | 63,082 | 03 Mar 2026 | Direct | ||
| Mark James Litton | LONA | Restricted Stock Units | Options Exercise | -100% | -22,254 | 0 | 03 Mar 2026 | Direct | ||
| Robert Renninger | LONA | Common Stock | Options Exercise | 30.3% | 3,900 | 16,757 | 03 Mar 2026 | Direct | ||
| Robert Renninger | LONA | Restricted Stock Units | Options Exercise | -100% | -3,900 | 0 | 03 Mar 2026 | Direct | ||
| Mark Worthington | LONA | Common Stock | Options Exercise | 41% | 5,726 | 19,704 | 03 Mar 2026 | Direct | ||
| Mark Worthington | LONA | Restricted Stock Units | Options Exercise | -100% | -5,726 | 0 | 03 Mar 2026 | Direct | ||
| Kevin Church | LONA | Common Stock | Options Exercise | 28.3% | 5,856 | 26,537 | 03 Mar 2026 | Direct | ||
| Kevin Church | LONA | Restricted Stock Units | Options Exercise | -100% | -5,856 | 0 | 03 Mar 2026 | Direct | ||
| Javier San Martin | LONA | Common Stock | Options Exercise | 72.8% | 7,418 | 17,607 | 03 Mar 2026 | Direct | ||
| Javier San Martin | LONA | Restricted Stock Units | Options Exercise | -100% | -7,418 | 0 | 03 Mar 2026 | Direct | ||
| Javier San Martin | ATHA | Common Stock | Sale | -13.9% | $11,311 | $6.88 | -1,644 | 10,189 | 02 Jan 2026 | Direct |
| Mark James Litton | ATHA | Common Stock | Sale | -5.96% | $17,792 | $6.88 | -2,586 | 40,828 | 02 Jan 2026 | Direct |
| Robert Renninger | ATHA | Common Stock | Sale | -2.26% | $2,043 | $6.88 | -297 | 12,857 | 02 Jan 2026 | Direct |
| Kevin Church | ATHA | Common Stock | Sale | -4.06% | $6,027 | $6.88 | -876 | 20,681 | 02 Jan 2026 | Direct |
| Mark Worthington | ATHA | Common Stock | Sale | -5.9% | $6,027 | $6.88 | -876 | 13,978 | 02 Jan 2026 | Direct |
| Javier San Martin | ATHA | Common Stock | Options Exercise | 65.1% | 4,667 | 11,833 | 31 Dec 2025 | Direct | ||
| Javier San Martin | ATHA | Restricted Stock Units | Options Exercise | -100% | -4,667 | 0 | 31 Dec 2025 | Direct | ||
| Mark James Litton | ATHA | Common Stock | Options Exercise | 33.2% | 10,834 | 43,414 | 31 Dec 2025 | Direct | ||
| Mark James Litton | ATHA | Restricted Stock Units | Options Exercise | -100% | -10,834 | 0 | 31 Dec 2025 | Direct | ||
| Robert Renninger | ATHA | Common Stock | Options Exercise | 10.4% | 1,236 | 13,154 | 31 Dec 2025 | Direct | ||
| Robert Renninger | ATHA | Restricted Stock Units | Options Exercise | -100% | -1,236 | 0 | 31 Dec 2025 | Direct | ||
| Kevin Church | ATHA | Common Stock | Options Exercise | 20.5% | 3,667 | 21,557 | 31 Dec 2025 | Direct | ||
| Kevin Church | ATHA | Restricted Stock Units | Options Exercise | -100% | -3,667 | 0 | 31 Dec 2025 | Direct | ||
| Mark Worthington | ATHA | Common Stock | Options Exercise | 32.8% | 3,667 | 14,854 | 31 Dec 2025 | Direct | ||
| Mark Worthington | ATHA | Restricted Stock Units | Options Exercise | -100% | -3,667 | 0 | 31 Dec 2025 | Direct | ||
| Robert Renninger | ATHA | Stock Option (Right to Buy) | Award | 34,358 | 34,358 | 24 Dec 2025 | Direct | |||
| Mark James Litton | ATHA | Stock Option (Right to Buy) | Award | 133,526 | 133,526 | 24 Dec 2025 | Direct | |||
| Kevin Church | ATHA | Stock Option (Right to Buy) | Award | 35,138 | 35,138 | 24 Dec 2025 | Direct | |||
| Javier San Martin | ATHA | Stock Option (Right to Buy) | Award | 44,508 | 44,508 | 24 Dec 2025 | Direct | |||
| Mark Worthington | ATHA | Stock Option (Right to Buy) | Award | 34,358 | 34,358 | 24 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.